The intranasal GHK-Cu treatment was found to delay cognitive impairment, reduce amyloid plaques, and lower inflammation levels in the frontal cortex and hippocampus .37 Randomized controlled trials in human patients are needed to confirm the benefit of GHK-Cu for cognitive decline and Alzheimers disease as well as to evaluate safe and effective human dosing (the human dose equivalent of 15mg/kg in mice would be ~1.2mg/kg, though data on this or any other dosing nasally in humans is not currently available), but preliminary animal trials are promising
We offer GHK-Cu and peptide therapy only under medical supervision, with dose , frequency and cycle individualised at consultation
Clients Experiencing Fatigue or Low Focus: If you feel tired more often than not, low B12 may be part of the picture
In addition to fat loss, AOD 9604 peptide therapy can help those struggling with other health problems, such as osteoarthritis, diabetes, bone damage, and depression
The catch is licensing
